Trials / Unknown
UnknownNCT04564937
The Study of Drug SCT510A in Patients With Wet Age-related Macular Degeneration (wAMD)
A Multicenter, Open-label, Multi-dose, Phase I / II Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Efficacy and Pharmacodynamic Characteristics of SCT510A in the Patients With Wet Age-related Macular Degeneration.
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter ，open-label, multi-dose study to evaluate the safety and tolerability in patients with wAMD treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody（SCT510A）
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCT510A | SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT |
Timeline
- Start date
- 2020-11-06
- Primary completion
- 2022-04-30
- Completion
- 2022-10-31
- First posted
- 2020-09-25
- Last updated
- 2020-09-25
Source: ClinicalTrials.gov record NCT04564937. Inclusion in this directory is not an endorsement.